Using albumin-bound paclitaxel to treat triple-negative breast cancer before surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of albumin-bound paclitaxel (nab-P) as a neoadjuvant therapy for patients with triple-negative breast cancer (TNBC). The study compares nab-P combined with carboplatin to traditional solvent-based paclitaxel with carboplatin. It aims to evaluate the therapeutic benefits of nab-P, which utilizes albumin nanoparticles to enhance drug delivery to tumors, potentially improving patient outcomes. The trial includes women aged 18-70 with confirmed TNBC and positive axillary lymph node metastasis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* breast cancer is confirmed by the mammography, and the immunohistochemical results of cancer tissues are negative for estrogen receptor, progesterone receptor and anti-human epidermal growth factor receptor 2;
* positive for axillary lymph node metastasis;
* 18-70 years of age, female;
* patients have good compliance with the planned treatment, who are volunteer to participate in the study, are willing to be treated with solvent-based paclitaxel or nab-P at random, and provide written informed consent with the premise of fully understanding the study protocol.

Exclusion Criteria:

* pregnant and lactating women;
* distant metastasis;
* patients with a history of other cancers or who have received radiotherapy on the chest;
* abnormalities in blood tests or presence of other symptoms of infection;
* allergy to paclitaxel;
* patients who have psychotropic drug abuse until now or those with a history of mental disorders;
* abnormalities in important organs such as the heart, lung, liver and kidney;
* patients who have participated in other clinical trials.

Where it's running

• Shengjing Hospital of China Medical University
  Shenyang, Liaoning, China Recruiting

Study contacts

• Principal investigator: Caigang Liu, M.D., Ph.D. — Shengjing Hospital
• Study coordinator: Xi Gu, M.D.
• Email: jadegx@163.com
• Phone: +86 18940255116

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.